Semaglutide review confirms sustained glycemic control, substantial weight loss, and cardiovascular/renal protection in metabolic disease.

Globally, obesity and type 2 diabetes mellitus (T2DM) impact over 800 million and 537 million individuals, respectively, highlighting a critical need for effective therapies. Current treatments often fall short in addressing the complex pathophysiological processes underlying metabolic dysregulation. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) like semaglutide have emerged as a significant advancement, targeting the GLP-1R pathway to improve glycemic control and promote weight loss, but their full spectrum of benefits and challenges requires comprehensive evaluation.

This comprehensive review consolidated evidence on semaglutide's mechanisms of action, clinical effectiveness across established and emerging applications, and safety profile. Researchers synthesized findings from numerous clinical studies to assess its role in metabolic dysregulation, including type 2 diabetes, obesity, and metabolic dysfunction-associated steatohepatitis (MASLD). The review also explored pharmacogenomic insights for personalized therapy and identified global accessibility challenges, aiming to provide a holistic view of semaglutide's current and future impact.

Clinical studies consistently demonstrate that semaglutide sustains glycemic control and promotes substantial weight loss. Beyond these primary effects, the review highlights significant cardiovascular and renal protective benefits. Recent FDA clearance marks semaglutide as the first therapeutic alternative for MASLD, an emerging application. While gastrointestinal side effects are the main tolerability concern, the overall risk-benefit profile strongly supports its increasing significance in metabolic therapy. Pharmacogenomic insights, though promising for personalized therapy, remain in the experimental stage. > Semaglutide has shown sustained glycemic control, substantial weight loss, and provides cardiovascular and renal protection, with recent FDA clearance for MASLD marking a significant therapeutic expansion. The review also noted that therapies for diabetes and obesity are cost-effective, but global accessibility challenges persist, limiting population-level effects.